GT Biopharma Inc GTBP 深 滬
等待開盤 08-13 09:30:00 美东时间
1.72
-0.020
-1.15%
華盛通- 最 高1.77
- 今 開1.77
- 成交量 5.15万股
- 最 低 1.68
- 昨 收 1.74
- 總市值 562.96万
- 52周最高 4.10
- 市盈率 靜 --
- 換手率 1.57%
- 52周最低 1.68
- 委 比 82.77%
- 總股本 327.30万
- 歷史最高 591.99
- 量 比 1.14
- 振 幅 5.17%
- 歷史最低 1.68
- 每 手 1
- 風險率 0.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多GT Biopharma Initiated Dosing In Cohort 3 Of Its Phase 1 Dose Escalation Trial Of GTB-3650 For Relapsed Or Refractory CD33 Expressing Hematologic Malignancies, Plans On Releasing Initial Phase 1 Results Later In 2025 Following Completion Of Additional Dose Cohorts
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed.The company plans
08-11 19:14
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
GT Biopharma announced the initiation of Cohort 3 in its Phase 1 trial for GTB-3650, its second-generation TriKE therapy for treating relapsed or refractory CD33+ hematologic malignancies. Cohorts 1 and 2 were successfully completed with no safety issues, and the first patient in Cohort 3 has completed the first week of treatment. Early results from Cohorts 1 and 2 show promising immune activity, with NK cell activation and expansion observed. Th...
08-11 11:00
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Mustang Bio (NASDAQ:MBIO) stock increased by 217.6% to $3.78 during Mo...
07-08 01:06
GT Biopharma Appoints New Member to its Board of Directors
GT Biopharma appoints David C. Mun-Gavin to its Board of Directors. Mun-Gavin, a seasoned executive with global experience in private banking and oil trading, brings valuable insights as the company prepares for clinical data readouts and pipeline expansion. GT Biopharma focuses on immuno-oncology therapeutics using its proprietary TriKE® NK cell engager platform.
06-13 13:00
GT Biopharma Expands Convertible Preferred Stock Offering
GT Biopharma ( ($GTBP) ) has provided an update. On May 12, 2025, GT Biopharma,...
05-28 04:55
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 72.6% to $0.47 during Wedne...
05-22 01:06
EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results
GTBP announces completion of dosing in Cohort 1 and start of dosing in Cohort 2 of Phase 1 trial for GTB-3650, showing potential for NK cell expansion and increased immunologic activity. Detailed results to be released in 2025. GTBP stock up 0.90%.
05-19 20:30
GT Biopharma Q1 EPS $(0.33) Beats $(0.64) Estimate
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.64) by 48.44 percent. This is a 79.88 percent increase over losses of $(1.64) per share from the
05-16 06:20
美股大行评级 | 潜在涨幅265%！Humacyte获机构上调目标价至17美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1078254829883351040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Benchmark：维持Humacyte(HUMA)"买入"评级，目标价从15美元升至17美元</p> <p>• Evercore ISI集团：维持BridgeBio Pharma(BBIO)"跑赢大市"评级，目标价从45
2024-12-24 09:30
